Ryman Healthcare (RYM) Stock Overview
Develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the older people in New Zealand and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
RYM Community Fair Values
Create NarrativeSee what 52 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ryman Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$2.29 |
| 52 Week High | NZ$3.05 |
| 52 Week Low | NZ$1.99 |
| Beta | 0.33 |
| 1 Month Change | 5.53% |
| 3 Month Change | -0.43% |
| 1 Year Change | 5.05% |
| 3 Year Change | -63.06% |
| 5 Year Change | -82.63% |
| Change since IPO | 748.15% |
Recent News & Updates
Narrative Update • May 30
RYM: Higher Discount Rate And Solid Margins Will Support Future Upside
Analysts have reduced their price target for Ryman Healthcare from NZ$3.16 to NZ$3.01. This reflects updated assumptions for fair value, a higher discount rate, adjusted revenue growth expectations, slightly lower profit margins, and a modestly lower future P/E multiple.
Narrative Update • May 16
RYM: Higher Discount Rate And P/E Assumptions Will Support Bullish Long Term Outlook
Analysts have reduced their NZ$ fair value estimate for Ryman Healthcare from NZ$2.95 to NZ$2.68, citing updated assumptions for discount rates, future P/E, revenue growth and profit margins. Valuation Changes Fair Value: NZ$ fair value estimate revised from NZ$2.95 to NZ$2.68, indicating a lower central valuation point for the stock.
Narrative Update • Apr 30
RYM: Higher Long Term Margins Will Support Improved Future Earnings Multiple
Analysts have nudged their NZ$ price target on Ryman Healthcare slightly higher, citing updated assumptions around discount rates, modest revenue growth adjustments, stronger long term profit margins, and a lower future P/E multiple as the main drivers of the change. Valuation Changes Fair Value: NZ$3.70 remains unchanged, with no adjustment to the overall fair value estimate.Recent updates
Narrative Update • May 30
RYM: Higher Discount Rate And Solid Margins Will Support Future Upside
Analysts have reduced their price target for Ryman Healthcare from NZ$3.16 to NZ$3.01. This reflects updated assumptions for fair value, a higher discount rate, adjusted revenue growth expectations, slightly lower profit margins, and a modestly lower future P/E multiple.Narrative Update • May 16
RYM: Higher Discount Rate And P/E Assumptions Will Support Bullish Long Term Outlook
Analysts have reduced their NZ$ fair value estimate for Ryman Healthcare from NZ$2.95 to NZ$2.68, citing updated assumptions for discount rates, future P/E, revenue growth and profit margins. Valuation Changes Fair Value: NZ$ fair value estimate revised from NZ$2.95 to NZ$2.68, indicating a lower central valuation point for the stock.Narrative Update • Apr 30
RYM: Higher Long Term Margins Will Support Improved Future Earnings Multiple
Analysts have nudged their NZ$ price target on Ryman Healthcare slightly higher, citing updated assumptions around discount rates, modest revenue growth adjustments, stronger long term profit margins, and a lower future P/E multiple as the main drivers of the change. Valuation Changes Fair Value: NZ$3.70 remains unchanged, with no adjustment to the overall fair value estimate.Narrative Update • Apr 15
RYM: Higher Discount Rate And Solid Margins Will Support Future Returns
Analysts have reduced their price target for Ryman Healthcare to NZ$3.16 from NZ$3.23. This change reflects updated assumptions for slightly higher discount rates, modestly different revenue growth expectations, and a small adjustment to projected profit margins and future P/E.Narrative Update • Apr 01
RYM: Reaffirmed Sales Guidance Will Support Bullish Long Term Outlook
Analysts have trimmed their NZ$ price target for Ryman Healthcare by about NZ$0.20, reflecting slightly higher discount rate assumptions and a more cautious view on margins, even as revenue growth expectations and future P/E settings remain under review. What's in the News Ryman Healthcare reaffirmed its sales guidance for occupation right agreements for fiscal 2026, keeping the target range at 1,300 to 1,400 agreements.Narrative Update • Mar 18
RYM: Higher Margins And Steady Sales Guidance Will Support Bullish Outlook
Analysts have nudged their NZ$ fair value estimate for Ryman Healthcare from NZ$2.94 to NZ$2.95, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Ryman Healthcare reaffirmed its sales guidance for occupation right agreements for fiscal 2026 at 1,300 to 1,400 agreements, indicating no change to its previously communicated range (Key Developments).Narrative Update • Mar 04
RYM: Reaffirmed Sales Guidance Will Support Improved Future Earnings Multiple
Analysts have nudged their NZ$ price target on Ryman Healthcare slightly higher, pointing to small changes in assumed discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated view. What's in the News Ryman Healthcare reaffirmed its fiscal 2026 sales guidance for occupation right agreements at 1,300 to 1,400, indicating no change from prior guidance.Narrative Update • Feb 18
RYM: Higher Margin Outlook Will Support Updated Sales Guidance
Analysts have lifted their NZ$ fair value estimate for Ryman Healthcare from NZ$3.50 to NZ$3.70, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Ryman Healthcare reaffirmed its fiscal 2026 sales guidance for occupation right agreements at 1,300 to 1,400, with guidance excluding expected relocations of fewer than 40 residents from Margaret Stoddart and Woodcote care centre closures, which will still appear in reported third quarter 2025 sales volumes (Key Developments).Narrative Update • Feb 03
RYM: Higher Margins And Flat Unit Sales Will Support Balanced Outlook
Analysts have made a small reduction to their price target for Ryman Healthcare to reflect updated assumptions. These include slightly higher long term revenue growth, a higher projected profit margin of about 66% and a modestly lower future P/E of roughly 5.8x.Analysis Article • Jan 21
Some Investors May Be Worried About Ryman Healthcare's (NZSE:RYM) Returns On Capital
If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? Businesses...Narrative Update • Jan 20
RYM: Stable Sales Guidance And Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Ryman Healthcare slightly higher, reflecting small adjustments to fair value, long term revenue growth and profit margin assumptions, along with a modestly different future P/E outlook. What's in the News Ryman Healthcare reaffirmed its occupation right agreement sales guidance for fiscal 2026 at 1,300 to 1,400, with guidance figures excluding resident relocations from the Margaret Stoddart and Woodcote villages following care centre closures (Key Developments).Narrative Update • Jan 06
RYM: Steady Sales Outlook And Margins Will Support Balanced Future Returns
Narrative Update: Ryman Healthcare Analyst Price Target The analyst price target for Ryman Healthcare is unchanged, as analysts kept their fair value estimate steady at $3.23 per share, reflecting consistent assumptions on the discount rate, revenue growth, profit margin and future P/E. What's in the News Ryman Healthcare Limited updated its sales guidance for full year 2025 to 1,300 to 1,400 units, indicating expectations for broadly flat total sales half on half in what the company describes as a mixed market (company guidance).Narrative Update • Dec 23
RYM: Higher Margins Will Support Balanced Outlook Amid Flat Unit Sales
Analysts have raised their price target on Ryman Healthcare by approximately 17 percent to reflect a higher assessed fair value of around $2.94 per share, supported by expectations of stronger profit margins despite slightly lower projected revenue growth and a modestly higher discount rate. What's in the News Ryman Healthcare Limited hosted an Analyst and Investor Day, providing updates on strategy, operating performance, and capital allocation priorities (company event).Narrative Update • Dec 09
RYM: Stronger Long Term Margins Will Support A More Optimistic Outlook
Analysts have nudged their price target on Ryman Healthcare higher to approximately NZ$3.23 from NZ$3.13. This reflects expectations of meaningfully stronger long term profit margins and a lower future earnings multiple, partly offset by more moderate revenue growth assumptions.Narrative Update • Nov 25
RYM: Updated Forecasts And Margins Will Support A Balanced Outlook
Narrative Update on Ryman Healthcare Analysts have revised Ryman Healthcare's fair value price target upward slightly from $3.07 to $3.13 per share. This adjustment is based on updated financial metrics and a continued reassessment of operational forecasts.Narrative Update • Nov 07
RYM: Stable Forecasts Will Support Current Share Price Levels
Narrative Update on Ryman Healthcare Analyst Price Target Analysts have maintained their price target for Ryman Healthcare at $3.07, with only minor adjustments to underlying assumptions. They cite stable forecasts for revenue growth and profit margins as reasons for the consistent valuation.Narrative Update • Oct 24
New Leadership And Pricing Reforms Will Boost Aged Care
Narrative Update: Ryman Healthcare Analysts have raised their fair value estimate for Ryman Healthcare from $2.98 to $3.07. This change reflects modest upward revisions to forecasts and is supported by slight improvements in the profit margin outlook.Narrative Update • Oct 10
New Leadership And Pricing Reforms Will Boost Aged Care
Analysts have raised their price target for Ryman Healthcare from $2.83 to $2.98, citing modest improvements in the company’s fair value, profit margin, and growth outlook. Valuation Changes Fair Value has risen slightly from NZ$2.83 to NZ$2.98.Analysis Article • Jul 03
Is Ryman Healthcare (NZSE:RYM) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Narrative • Apr 22
New Leadership And Pricing Reforms Will Boost Aged Care
New leadership is focused on effective governance and strategic alignment, aiming to enhance earnings and shareholder value through transformation efforts.Analysis Article • Nov 25
Is Ryman Healthcare Limited (NZSE:RYM) Trading At A 42% Discount?
Key Insights Ryman Healthcare's estimated fair value is NZ$8.72 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Aug 16
Is Ryman Healthcare (NZSE:RYM) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Jul 12
Are Investors Undervaluing Ryman Healthcare Limited (NZSE:RYM) By 47%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Ryman Healthcare fair value estimate is NZ$7.33 Ryman...Analysis Article • Jun 05
Ryman Healthcare's (NZSE:RYM) Soft Earnings Don't Show The Whole Picture
Ryman Healthcare Limited's ( NZSE:RYM ) earnings announcement last week didn't impress shareholders. While the headline...Analysis Article • May 21
Little Excitement Around Ryman Healthcare Limited's (NZSE:RYM) Earnings
Ryman Healthcare Limited's ( NZSE:RYM ) price-to-earnings (or "P/E") ratio of 10.9x might make it look like a buy right...Analysis Article • Apr 24
Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint A Concerning Picture
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analysis Article • Feb 08
Ryman Healthcare Limited's (NZSE:RYM) P/E Is On The Mark
It's not a stretch to say that Ryman Healthcare Limited's ( NZSE:RYM ) price-to-earnings (or "P/E") ratio of 15.3x...Analysis Article • Jan 07
Here's Why Ryman Healthcare (NZSE:RYM) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Dec 20
Capital Allocation Trends At Ryman Healthcare (NZSE:RYM) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Analysis Article • Sep 11
What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?
Ryman Healthcare Limited ( NZSE:RYM ), might not be a large cap stock, but it saw significant share price movement...Analysis Article • Jul 04
Ryman Healthcare (NZSE:RYM) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • May 30
Ryman Healthcare Limited (NZSE:RYM) Shares Could Be 24% Below Their Intrinsic Value Estimate
Key Insights Ryman Healthcare's estimated fair value is NZ$8.21 based on 2 Stage Free Cash Flow to Equity Ryman...Analysis Article • Aug 26
Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?
Ryman Healthcare Limited ( NZSE:RYM ), is not the largest company out there, but it saw significant share price...Analysis Article • May 04
When Should You Buy Ryman Healthcare Limited (NZSE:RYM)?
While Ryman Healthcare Limited ( NZSE:RYM ) might not be the most widely known stock at the moment, it received a lot...Analysis Article • Jan 08
What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?
While Ryman Healthcare Limited ( NZSE:RYM ) might not be the most widely known stock at the moment, it received a lot...Shareholder Returns
| RYM | NZ Healthcare | NZ Market | |
|---|---|---|---|
| 7D | 0.4% | -1.1% | -0.4% |
| 1Y | 5.0% | -30.7% | 4.1% |
Return vs Industry: RYM exceeded the NZ Healthcare industry which returned -30.7% over the past year.
Return vs Market: RYM matched the NZ Market which returned 4.1% over the past year.
Price Volatility
| RYM volatility | |
|---|---|
| RYM Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 5.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in NZ Market | 8.9% |
| 10% least volatile stocks in NZ Market | 2.8% |
Stable Share Price: RYM has not had significant price volatility in the past 3 months compared to the NZ market.
Volatility Over Time: RYM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Naomi James | www.rymanhealthcare.co.nz |
Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the older people in New Zealand and Australia. The company’s villages provide apartments and townhouses, and assisted-living in serviced apartments, and care center, which offers rest homes, hospitals, specialist dementia care, and respite care services. Ryman Healthcare Limited was founded in 1984 and is based in Christchurch, New Zealand.
Ryman Healthcare Limited Fundamentals Summary
| RYM fundamental statistics | |
|---|---|
| Market cap | NZ$2.29b |
| Earnings (TTM) | -NZ$171.34m |
| Revenue (TTM) | NZ$854.47m |
2.7x
P/S Ratio-13.6x
P/E RatioIs RYM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RYM income statement (TTM) | |
|---|---|
| Revenue | NZ$854.47m |
| Cost of Revenue | NZ$773.69m |
| Gross Profit | NZ$80.78m |
| Other Expenses | NZ$252.12m |
| Earnings | -NZ$171.34m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 9.45% |
| Net Profit Margin | -20.05% |
| Debt/Equity Ratio | 190.1% |
How did RYM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/04 06:15 |
| End of Day Share Price | 2026/06/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ryman Healthcare Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen Ridgewell | Deutsche Bank |
| Will Twiss | Forsyth Barr Group Ltd. |
| Matthew Henry | Goldman Sachs |